BioCopy is now also registered as an official trademark in the US. This will strengthen our company’s prospects for the world's largest markets of biomedical innovation.
The BioCopy technology is unique. It enables the highly parallel production of thousands of proteins on single chips. In the future, vaccines and T-cell based therapeutics can be developed even faster and more accurately with our technology.
BioCopy is expanding its T-cell focus to help develop individual therapies as comprehensively, rapidly, accurately and securely as possible. We are confident that we will be able to meet these challenges with our technology.